A review of the quality of care provided to patients aged over 16 years with a new diagnosis of pulmonary embolism
Due to the COVID 19 situation, hundreds of warfarin patients are getting in touch with ACUK and posting on our Health Unlocked social platform asking if they can self-test and how they can get a monitor.
Patient accounts and discussion surrounding the issues of VTE from diagnosis through to treatment and the lack of knowledge and support within the public and healthcare professional communities.
These stockings are designed to reduce the risk of blood clots (deep vein thrombosis) in the legs at times when you are a higher risk of blood clots, such as undergoing an operation or being a medical
patient that is not mobile.
An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial
Are you taking anticoagulants and thinking about having aesthetics treatments then our new fact sheet is a must read before you make a decision to go ahead.
Know the facts of Atrial Fibrillation and understand the risk.
Blood clots pose a very significant risk to cancer patients. Teresa talks about her story.
If you are worried about clots, immediately contact your healthcare team.
There is a theory that people with caring responsibilities go through stages of caring. Of course we're all different and this won't apply to everyone. Much depends on the way caring happens.
If you are taking anticoagulation to treat, prevent or reduce the risk of blood clots or stroke risk, you can help manage your treatment with the following tips to aid a stress free trip.
The NHS Clinical Commissioners (the independent collective voice of clinical commissioners) have issued a Healthcare professional’s quick reference guide for conditions for which over the counter items should not be routinely prescribed in primary care.
The term ‘atrial flutter’ is used to describe an unusually fast and irregular heart rhythm. The problem originates in the atria (the upper chambers of the heart) and is brought about by a fault in their electrical circuits.
Clots are serious but effective treatments are available. Help promote the signs to watch out for.
Cancer-Associated Thrombosis (CAT) is a blood clot that occurs in someone with cancer. People who have cancer have a greater risk of developing a blood clot.
An overview of what to do if you are going into hospital. Ask for a risk assessment and follows these suggestions to help yourself.
An overview of Anticoagulation UK's mission statement., outlining our aims and objectives.
Help raise awareness of Blood Clots to members of your local Golf or sporting society.
Atrial fibrillation (AF) is the most commonly occurring cardiac arrhythmia, and a major cause of stroke, cardiovascular morbidity and mortality. More than 33.5 million people worldwide suffer from AF with 5 million new cases each year.
Nearly three-quarters of respondents (72%) said that, before taking part in the survey, they were not aware that people with cancer have a higher than normal risk of developing thrombosis; and overall, amongst all respondents, the average (mean) rating of their understanding of cancer-associated thrombosis is only 4.1 out of 10 (the median is 4 out of 10).
The dose of direct acting oral anticoagulants (DOACs) recommended depends on the indication, concomitant medication and a number of individual patient factors. The dose prescribed should be in line with licensed recommendations to reduce both the risk of thromboembolic events and bleeding complications.
As part of the wider work in improving the identification and management of atrial fibrillation (AF) across London, high quality anticoagulation services are seen as a priority to ensure that patients with AF at high risk of stroke are optimally protected to prevent ischaemic stroke, avoid adverse events related to anticoagulant treatment, and to ensure that patients are supported with choice, education, access and adherence to treatment.
This report gathers information obtained through Freedom of Information (FOI) Act requests submitted in July 2017 to 149 secondary care NHS Trusts in England. The findings and analysis are based on the Trusts’ responses to the FOI request, which were received by the end of August 2017.
Pursuing our aims to help patients and healthcare professional involved in anticoagulation service provision, Anticoagulation UK has produced this animation which provides a comprehensive overview of the current landscape of anticoagulation treatments, associated conditions and the importance of engaging the patient in the decision making process.
A deep vein thrombosis (DVT) occurs when a blood clot forms in a vein and causes a blockage. A DVT usually develops in the calf vein in the leg, but it sometimes also occurs above the knee. A DVT can also develop in other deep veins in your body.
If you are being admitted into hospital in the near future or you are currently an inpatient, you may be at risk of developing a blood clot. This guide is intended to help you to learn more about blood clots which can form in your body after illness or surgery and the choice of prevention therapies that are available to you.
El cáncer es una enfermedad con muchos aspectos a tener en cuenta. Aspectos relacionados con el tratamiento, la enfermedad misma o sus implicaciones en la vida diaria. Uno de los aspectos importantes es la posibilidad de desarrollar una trombosis (coágulo de sangre). Esto se conoce como trombosis asociada al cáncer (CAT).
O cancro é uma doença com muitos aspetos a considerar. Esses aspetos relacionam-se com o tratamento, com a própria doença e com implicações nas atividades da vida diária. Um dos aspetos mais
importantes é a possibilidade de desenvolver um coágulo de sangue. Esta condição é conhecida como trombose associada ao cancro (CAT).
Ο καρκίνος είναι μια ασθένεια με πολλές πτυχές οι οποίες πρέπει να λαμβάνονται υπόψη. Αφορούν τη θεραπευτική αγωγή, αυτή καθεαυτήν την ασθένεια και τις συνέπειες στον καθημερινό σας τρόπο ζωής. Μία από τις σημαντικότερες πτυχές είναι η πιθανότητα σχηματισμού θρόμβου αίματος. Η περίπτωση αυτή είναι γνωστή ως Φλεβική Θρομβοεμβολή συσχετιζόμενη με Καρκίνο (ΦΘΕ/Κ).
Krebs ist eine Erkrankung, bei der viele Gesichtspunkte zu berücksichtigen sind, die Behandlung, die Erkrankung selbst sowie die Auswirkungen auf Ihr tägliches Leben. Ein wichtiger Aspekt ist die Möglichkeit, ein Blutgerinnsel zu entwickeln. Diesen Zusammenhang bezeichnet man auch als ein durch Krebs bedingtes Thromboserisiko.
Le cancer est une maladie avec de nombreux aspects à prendre en compte. Ces derniers concernent le traitement, la maladie elle-même et les implications sur votre style de vie quotidien. L’un des aspects les plus importants est le développement possible de caillots sanguins. Cette complication doit être connue et reconnue : la Thrombose Associée au Cancer (TAC).
A guide to Anticoagulation Therapy to Reduce the Risk of Blood Clots. What are Anticoagulants ? Risk Factors. Blood Clots. Treatments.
Rivaroxaban is an anticoagulant medicine that helps to prevent blood from clotting. It does this by interfering with a substance in the body called Factor Xa which is involved in the development of blood clots.
Edoxaban is an anticoagulant medicine that helps to prevent blood from clotting. It does this by interfering with a substance in the body called Factor Xa which is involved in the development of blood clots.
Dabigatran is an oral anticoagulant. It is a direct thrombin inhibitor (DOAC) and helps to prevent blood clots from forming by interfering with thrombin which is an important component of blood clotting.
Apixaban is an anticoagulant that helps to prevent blood clots
from forming by blocking Factor Xa, which is an important
component of blood clotting.
This booklet has been developed to explain the increased risk of developing blood clots (also known as deep vein thrombosis) in people who have been hospitalised for any reason.
If you are advised that you need to take an anticoagulant, it can be helpful and reassuring to discuss the options with your doctor to ensure you are able to make the right choice with their guidance.
This is an educational video funded by LEO Pharma and developed in partnership with Anticoagulation UK (formerly Anticoagulation Europe) with advice of both parties and healthcare professionals.
Fideo addysgol yw hwn wedi'i ariannu gan LEO Pharma a'i ddatbygu mewn partneriaeth ag Anticoagultion UK (gynt Anticoagulation Europe) gyda chyngor cleifion a gweithwyr proffesiynol gofal iechyd.
If you are experiencing atrial fi brillation, however, you may notice your heartbeat becoming irregular and speeding up for no apparent reason. These feelings or "palpitations" may occur constantly or only from time to time. They are unpleasant and worrying and they should not be ignored as they may mean that something is seriously wrong with your heart.
This is a question commonly asked following diagnosis of deep vein thrombosis (DVT) or pulmonary embolism (PE).
A stroke is a serious medical condition that occurs when the blood supply to part of the brain is cut off. It can affect our bodily functions, thought processing, ability to learn, communication and emotions.
Warfarin is a medication that affects clotting factors that are produced in the liver. This results in your blood taking longer to clot and less likely to form harmful clots.
It is very important that your dentist knows what medications you are taking and what medical conditions you have. By dentist we also mean your dental hygienist or dental therapist.
Warfarin tablets in the UK are colour coded to help you take the correct dose. They are available in 5mg (pink), 3mg (blue), 1mg (light brown) and 0.5mg (white). You should remember what dose you
are taking and not just the colour.
Direct Oral Anticoagulants (DOACS) Apixaban, Dabigatran, Edoxaban and Rivaroxaban and your dental treatment.
There are four valves in the heart. Each valve consists of two or three flaps or cusps of tissue that open to let the blood through then seal shut to prevent backflow allowing a one-way flow of blood through the heart.
This year has seen a number of developments in relation to the NHS and healthcare more widely. The NHS turned 70, Matt Hancock MP became the new Secretary of State for Health, and Sustainability and Transformation Partnerships (STPs) and Integrated Care Systems (ICSs) have once again been tasked with developing updated healthcare plans for their respective areas.
Next year, the NHS will turn 70 and it is clear that this important milestone comes at a time of unprecedented challenge. Britain’s ageing population and the rise in patients with long-term conditions are stretching the capacity of the NHS and social care services, and a difficult funding settlement is creating pressure to do more with less.
Since its inception in 2006, the APPTG has produced reports to support the implementation of best practice in VTE prevention in the NHS. Drawing on evidence gathered by surveys of Acute Trusts and CCGs, local case studies and official national statistics, our reports provide a comprehensive overview of progress in implementing best practice; identify areas for future improvement; and offer recommendations on what more can be done to ensure that NHS services are underpinned by high quality VTE prevention and management.
As the Chair of the All-Party Parliamentary Thrombosis Group (APPTG), I am delighted to launch this report into the current standards for prevention and management of VTE within care homes in England.
In 2012 the first version of the Commissioning effective anticoagulation services for the future, resource pack was developed. This new revised version has been developed and changed significantly since November 2012.
The APPTG has long been concerned about the risks of VTE in cancer patients, and in particular that awareness of the issue is low in the NHS. This new report was commissioned to establish
the links between cancer, cancer treatment and the increased risks of VTE in England and Wales. The APPTG was also eager to establish if hospitals are providing patients with information
about the risks; and if pathways are in place to manage patients who develop clots whilst undergoing treatment.
As the Chair of the All-Party Parliamentary Thrombosis Group, I am delighted to launch our first report into the management of venous thromboembolism (VTE) in the NHS.